EIKN vs NBTX: fair value comparison
Eikon Therapeutics, Inc. and Nanobiotix S.A. · Updated 2026-10-19
EIKN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. NBTX reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, EIKN currently ranks higher by quality score.
| EIKN | NBTX | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $7.42 | $27.90 |
| 12-month range | $7.41–$15.00 | $15.08–$55.07 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #287 of 301 Healthcare | #289 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Low |
| Margin trend | — | Stable |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: EIKN fair value analysis · NBTX fair value analysis